if I invest in tenaya therapeutics righjt now would there be a chacne it gets delisted?

The risk of Tenaya Therapeutics being delisted from Nasdaq is a significant concern, and it's crucial to consider this potentiality when evaluating your investment decision. Here are the key points to consider:

1. **Current Stock Price and Market Capitalization**: As of July 31, 2025, Tenaya Therapeutics' stock price is $0.676, and the market capitalization is $109.96 million.

|code|Ticker|Name|Date|Market Cap|Closing Price|market_code|
|---|---|---|---|---|---|---|
|TNYA|TNYA.O|Tenaya Therapeutics|20240801|2.51261805795E8|3.185|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240802|2.2325617281E8|2.83|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240805|2.0116722285E8|2.55|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240806|2.130005889E8|2.7|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240807|2.0116722285E8|2.55|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240808|2.1142280676E8|2.68|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240809|2.0905613355E8|2.65|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240812|2.1457837104E8|2.72|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240813|2.4061177635E8|3.05|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240814|2.2325617281E8|2.83|185|

2. **Nasdaq Delisting Notification**: Tenaya Therapeutics received a notification from Nasdaq indicating a potential delisting due to its stock price not meeting the minimum bid price requirement. The company has been given a 180-day period to regain compliance.
3. **Plan to Regain Compliance**: Tenaya Therapeutics is considering options to rectify the bid price deficiency and is committed to efforts to sustain its Nasdaq listing. This may include a potential reverse stock split.
4. **Analyst Ratings and Price Targets**: Analysts have lowered their price targets for Tenaya Therapeutics to $6 and $5, respectively, while maintaining a Buy rating. These price targets are below the current trading price, indicating that analysts believe the stock may face downward pressure.
5. **Financial Performance and Valuation Metrics**: Tenaya Therapeutics has a negative P/E ratio, indicating that it is not currently profitable. The company's net income and diluted EPS have shown a decline over the 5-year period.

|code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code|
|---|---|---|---|---|---|---|---|
|TNYA|TNYA.O|Tenaya Therapeutics|2024 Q2|11.536264991433466||24.44444444444444|185|
|TNYA|TNYA.O|Tenaya Therapeutics|2024 Q3|12.040627251827198||23.076923076923084|185|
|TNYA|TNYA.O|Tenaya Therapeutics|2024 Q4|20.374143978620342|||185|
|TNYA|TNYA.O|Tenaya Therapeutics|2025 Q1|16.643912126101526||40.00000000000001|185|

|code|Ticker|Name|Date|P/E(TTM)|P/S|Price to Book Ratio|market_code|
|---|---|---|---|---|---|---|---|
|TNYA|TNYA.O|Tenaya Therapeutics|20240801|-2.016952||1.5809732316980654|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240802|-1.792142||1.4047580049310913|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240805|-1.614828||1.265771347199393|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240806|-1.709818||1.3402284852699458|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240807|-1.614828||1.265771347199393|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240808|-1.697152||1.5778174642715883|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240809|-1.678154||1.5601553284775032|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240812|-1.722483||1.6013669786637015|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240813|-1.931461||1.7956504723986357|185|
|TNYA|TNYA.O|Tenaya Therapeutics|20240814|-1.792142||1.666128143242013|185|

6. **Clinical Trial Progress and Potential Upside**: Despite the risks of delisting, Tenaya Therapeutics has made significant progress in its clinical trials, with positive safety recommendations from DSMBs for both TN-201 and TN-401. The company's gene therapies are targeting rare cardiac diseases, which could offer a significant market opportunity if approved.

In conclusion, while Tenaya Therapeutics has the potential for growth driven by its clinical trial progress, the risk of delisting is a real concern. The company's stock price is currently above the analyst price targets, which suggests that the stock may face downward pressure in the near term. If you choose to invest in Tenaya Therapeutics right now, it's important to be aware of the potential for delisting and the risks associated with it. Consider your risk tolerance and investment horizon carefully before making a decision.